Vetoquinol SA
PAR:VETO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vetoquinol SA
Total Liabilities & Equity
Vetoquinol SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vetoquinol SA
PAR:VETO
|
Total Liabilities & Equity
€725.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Sanofi SA
PAR:SAN
|
Total Liabilities & Equity
€126.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Ipsen SA
PAR:IPN
|
Total Liabilities & Equity
€6.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
|
|
Virbac SA
PAR:VIRP
|
Total Liabilities & Equity
€1.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
3%
|
|
|
Boiron SA
PAR:BOI
|
Total Liabilities & Equity
€561.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Medincell SA
PAR:MEDCL
|
Total Liabilities & Equity
€74.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Vetoquinol SA
Glance View
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
See Also
What is Vetoquinol SA's Total Liabilities & Equity?
Total Liabilities & Equity
725.8m
EUR
Based on the financial report for Jun 30, 2025, Vetoquinol SA's Total Liabilities & Equity amounts to 725.8m EUR.
What is Vetoquinol SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
6%
Over the last year, the Total Liabilities & Equity growth was 3%. The average annual Total Liabilities & Equity growth rates for Vetoquinol SA have been 5% over the past three years , 7% over the past five years , and 6% over the past ten years .
